Should I Buy CERS? CERS 2026 Analysis

Should You Buy Cerus Corp (CERS) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

2.200

1 Day change

2.80%

52 Week Range

2.960

Analysis Updated At

2026/02/04

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Not a good buy right now for an impatient buyer: the near-term technical setup is weak (bearish/expanding MACD histogram, price below pivot 2.47), and the pattern-based forecast points to a negative 1-month bias (-6.5%).
Options positioning is very call-heavy (bullish sentiment), but it’s paired with very high implied volatility, which often means the market is paying up for upside and the stock can still drift lower.
Intellectia Proprietary Trading Signals
- AI Stock Picker: no signal on given stock today.
- SwingMax: No signal on given stock recently.
Net: avoid initiating a new position pre-market at ~2.35; it’s a HOLD/WAIT rather than a buy.

Technical Analysis

Trend/momentum: MACD histogram at -0.0398 and negatively expanding → bearish momentum is strengthening.
RSI(6) at 41.14 → neutral-to-weak (not oversold enough to signal a high-conviction bounce).
Moving averages: converging → no clear trend strength; supports the “choppy-to-down” read.
Key levels: Pivot 2.47 is the main near-term bull/bear line.
- Support: S1 2.281 (near current price area), then S2 2.164.
- Resistance: R1 2.659, then R2 2.776.
Statistical/pattern view: similar-pattern study suggests +0.65% next day, +1.86% next week, but -6.5% over the next month → short pop risk, medium-term downside risk.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Sentiment (open interest): Put/Call OI ratio = 0.05 (puts very small vs calls) → strongly bullish positioning.
Sentiment (volume): Put/Call volume ratio = 0.0 with 75 calls and 0 puts → one-sided bullish day flow.
Volatility: 30D IV 152.9 vs historical vol 80.99; IV percentile 80 → options are expensive and imply large moves; bullish flow may already be “priced in.”
Activity: today’s volume 75 vs 30D average (ratio 68.18) suggests activity is not unusually high; OI ~9,131 and slightly above its recent average (103.19).

Technical Summary

Sell

Buy

Positive Catalysts

- Analyst catalyst: TD Cowen highlights the Intercept Fibrinogen Complex franchise as an underappreciated long-term growth engine and expects the BCA partnership to accelerate adoption/scalability/profitability.
- Growth: 2025/Q3 revenue +18.91% YoY indicates continued top-line momentum.
- Potential event catalyst ahead: next earnings on 2026-03-02 (after hours) can reset expectations if margins/profitability improve.

Neutral/Negative Catalysts

- No recent news catalysts in the past week to reverse the current bearish technical momentum.
- Medium-term bias from pattern study is negative (-6.5% over the next month).
- Profitability/margins: 2025/Q3 gross margin down YoY and earnings power weakened (EPS down to 0), which can cap multiple expansion.
- Options are very high IV (expensive) which can coincide with sharp swings and post-earnings/expectations risk.

Financial Performance

Latest quarter: 2025/Q3.
Revenue: $60.237M, up 18.91% YoY → strong growth trend.
Net income: -$0.019M, down 99.35% YoY → profitability deteriorated materially vs prior year.
EPS: 0, down 100% YoY → earnings power weakened.
Gross margin: 59.23%, down 2.71% YoY → modest margin compression despite revenue growth.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Recent trend: only one recent update provided.
2025-12-23 TD Cowen: Buy, price target $5.
Wall Street pro view (pros): sees durable double-digit revenue growth and believes valuation is discounted; expects BCA partnership to accelerate adoption/profitability.
Wall Street pro view (cons): limited broader analyst trend data here; fundamentals show margin compression and weaker profitability in the latest quarter, which may be why the stock isn’t acting strongly despite the bullish thesis.

4 Analyst Rating

Wall Street analysts forecast CERS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CERS is 4.5 USD with a low forecast of 4 USD and a high forecast of 5 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

3 Buy

1 Hold

0 Sell

Strong Buy

Current: 2.140

Low

Averages

4.5

High

Current: 2.140

Low

Averages

4.5

High

TD Cowen

Buy

maintain

AI Analysis

2025-12-23

Reason

TD Cowen

Price Target

AI Analysis

2025-12-23

maintain

Buy

Reason

TD Cowen says that Cerus' Intercept Fibrinogen Complex franchise represents an underappreciated long-term growth engine. The firm expects the newly announced BCA partnership to materially accelerate its adoption, scalability, and profitability across the U.S. blood center ecosystem. TD Cowen has increased confidence in the sustainability of Cerus' double digit revenue growth trajectory and views the current discounted valuation as attractive. The firm has a Buy rating on the shares with a price target of $5.

Cantor Fitzgerald

Ross Osborn

Buy

Reiterates

2025-02-21

Reason

Cantor Fitzgerald

Ross Osborn

Price Target

2025-02-21

Reiterates

Buy

Reason

CERS Should I Buy

CERS Should I Buy

Should You Buy Cerus Corp (CERS) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch